Canadian Beef Cattle Research, Market Development and Promotion Agency

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

Retrieved on:

Tuesday, September 19, 2023

Small RNA, Conditional sentence, ASO, Canadian Beef Cattle Research, Market Development and Promotion Agency, CRISPR, Growth, Cardiovascular disease, Therapy, Novartis, Oligonucleotide, Carbon, Automation, Fine chemical

SEOUL, South Korea, Sept. 19, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.

Key Points:

SEOUL, South Korea, Sept. 19, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.
To diversify its operational scope, the new facility will be designed to accommodate different scales of production.
With a total investment of $110 million USD, the construction of the new oligonucleotide facility at ST Pharm Banwol Campus planned for completion in 2025 will cover approximately 3,300 squares meters (10,900㎡), standing at a height of 60 meters across 7 floors.
Furthermore, ST Pharm is dedicated to reducing its carbon footprint and advancing sustainability.

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

Retrieved on:

Tuesday, September 19, 2023

SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.

Key Points:

SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.
To diversify its operational scope, the new facility will be designed to accommodate different scales of production.
With a total investment of $110 million USD, the construction of the new oligonucleotide facility at ST Pharm Banwol Campus planned for completion in 2025 will cover approximately 3,300 squares meters (10,900㎡), standing at a height of 60 meters across 7 floors.
Furthermore, ST Pharm is dedicated to reducing its carbon footprint and advancing sustainability.

Ecolab Appoints Eric Green to Board of Directors

Retrieved on:

Thursday, December 8, 2022

The board of directors of Ecolab Inc. has appointed Eric Green to the Ecolab board, effective December 8, 2022.

Key Points:

The board of directors of Ecolab Inc. has appointed Eric Green to the Ecolab board, effective December 8, 2022.
He is joining a strong Board that is focused on delivering growth for all Ecolab stakeholders, said Christophe Beck, Ecolab chairman and chief executive officer.
Consistent with Ecolabs other recent appointments, Eric will bring new insights, global operating experience and public company leadership expertise to the Board, said Jeffrey Ettinger, lead independent director for the Ecolab board.
Ecolab is an impressive company and I am honored to join this accomplished Board at such an important time in its history, said Mr. Green.

Mr. Lube donation helps keep BGC Canada Club vehicles safe on the road this winter

Retrieved on:

Tuesday, November 15, 2022

BGC Club staff rely on their vans to deliver vital programming to youth in 70+ communities across Canada.

Key Points:

BGC Club staff rely on their vans to deliver vital programming to youth in 70+ communities across Canada.
To help get their fleet ready for the upcoming winter season, Mr. Lube offered free new Continental Tire winter tires and installation to their long-standing partner.
A recent survey by Mr. Lube further highlights the importance of all vehicles getting ready for the upcoming winter season.
"We need to do everything we can to make our vehicles as safe as possible," says Rachael MacKenzie-Neill, Vice President, Marketing & Development, BGC Canada.

Touchstone Research & SUP3RNATURAL Announce Strategic Partnership

Retrieved on:

Tuesday, August 23, 2022

Partnership, Research, Technology, Strategic planning, Touchstone, Qualitative research, Canadian Beef Cattle Research, Market Development and Promotion Agency, NEW, Music, News, Trailer Park, Inc., Industry, Efficiency, Marketing, Retail, Entertainment, Marketing

LOS ANGELES and NEW YORK, Aug. 23, 2022 /PRNewswire/ -- Touchstone Research is a tech driven full service marketing research firm delivering next gen research to the world's largest brands, marketers and agencies. Increasingly, clients are looking for a seamless partner experience that goes from producing Research to producing the creative and campaign briefs based on those findings for Marketing.

Key Points:

LOS ANGELES and NEW YORK, Aug. 23, 2022 /PRNewswire/ --Touchstone Research is a tech driven full service marketing research firm delivering next gen research to the world's largest brands, marketers and agencies.
Touchstone Research, who provides consumer research services for the world's largest media & entertainment, technology, youth and family brands, will expand its ability to support clients with the SUP3RNATURAL partnership.
"We're partnering with SUP3RNATURAL to bring our clients added value when it comes to actioning research in service of Marketing," said Aaron Burch CEO of Touchstone Research.
Touchstone Research is a leading provider in global quantitative and qualitative research, specializing in full-service quantitative survey services, online insight communities, user experience, and ethnographic research.

Lavva Plant-Based Yogurt Announces Strategic Partnership with Next In Natural

Retrieved on:

Wednesday, August 10, 2022

NEW YORK, Aug. 10, 2022 /PRNewswire/ --Plant-based yogurt company Lavva announces it has been acquired by lead operating partner Next in Natural, in concert with Lavva Founder and Chief Growth Officer Liz Fisher.

Key Points:

NEW YORK, Aug. 10, 2022 /PRNewswire/ --Plant-based yogurt company Lavva announces it has been acquired by lead operating partner Next in Natural, in concert with Lavva Founder and Chief Growth Officer Liz Fisher.
The new alliance brings forth a team of strategic investors, including David Heller, Art Wrubel, and David Blitzer.
"Lavva is what's next in natural delicious and nutritious plant-based products aligned with consumer demand for clean, whole food, functional, regenerative ingredients, and convenience," states Lichtenstein.
Lavva is available exclusively at visionary retailers and D2C partners seeking to elevate their yogurt selection.

DGAP-News: flatexDEGIRO with strong growth and high profitability in challenging market environment

Retrieved on:

Tuesday, July 12, 2022

Together, flatexDEGIRO and Whitebox will offer flatexDEGIRO customers a fully digital investment solution.

Key Points:

Together, flatexDEGIRO and Whitebox will offer flatexDEGIRO customers a fully digital investment solution.
Even in times of extremely strong growth over the past 36months, the excellent quality of the customer base was thus maintained.
All regions with significant customer growth, especially the Growth Markets
With a presence in 18 European countries, flatexDEGIRO structures its market presence according to the size and growth dynamics of its customer base.
The strongest growth opportunities are seen in France, Spain, Portugal, Italy, Switzerland, Ireland and the United Kingdom (Growth Markets).

West Names President and CEO Eric M. Green as Chair of the Board

Retrieved on:

Monday, February 28, 2022

"Eric has successfully led the company since 2015, while advancing the Company's mission and increasing shareholder value," said Patrick Zenner, Chair of the Board, West.

Key Points:

"Eric has successfully led the company since 2015, while advancing the Company's mission and increasing shareholder value," said Patrick Zenner, Chair of the Board, West.
"I am confident that Eric will lead the Board with the collaborative style and strategic, operating mindset demonstrated over his tenure as CEO.
Aligned to West's corporate governance principles, when the Chair and role of CEO are combined, the Board will appoint a Lead Independent Director.
"We would like to extend our appreciation to Pat for his long-standing commitment and unrelenting dedication as Chair to our Board and West.

DGAP-News: flatexDEGIRO with next record year and strong growth outlook for 2022

Retrieved on:

Wednesday, January 5, 2022

Nordic Growth Market, Foundation, Canadian Beef Cattle Research, Market Development and Promotion Agency, WKN, CEO, AG, ISIN, Acceleration, Ticker, CFO

Management bases this expectation on conservative assumptions regarding this year's market volatility, resulting in an average customer trading activity of approx.

Key Points:

Management bases this expectation on conservative assumptions regarding this year's market volatility, resulting in an average customer trading activity of approx.
Just the continuation of this trend would already bring us to the lower end of our account growth guidance in 2022.
With presence in 18 European countries, flatexDEGIRO clusters its market presence based on the size and growth dynamics of its customer base.
The strongest growth opportunity is seen in France, Belgium, Spain, Portugal, Italy, Switzerland, Ireland and the UK (Growth Markets).

ST Pharm announces expansion of oligonucleotide facility, taking a leap towards the world's largest oligonucleotide CDMO

Retrieved on:

Monday, November 29, 2021

Research, Degenerative disease, API, Novartis, Hypertension, Pfizer, ATA, Alnylam Pharmaceuticals, Therapy, Canadian Beef Cattle Research, Market Development and Promotion Agency, HBV, Efficiency, Hyperlipidemia, FDA, CDMO, Growth, Fine chemical

ST Pharm will invest in total $126 million USD at Banwol campus located in Ansan until 2025 and thiswill construct the second oligonucleotide plant with four to six large production lines.

Key Points:

ST Pharm will invest in total $126 million USD at Banwol campus located in Ansan until 2025 and thiswill construct the second oligonucleotide plant with four to six large production lines.
In 2018, ST Pharm has established its first oligonucleotide plant at Banwol campus and this had a production capacity of 1.5 mole per year.
In 2020, ST Pharm has decided to retrofit the plant for further capacity expansion and when completed, ST Pharm will have a production capacity of 6.4 mole per year.
Furthermore, the establishment of the second oligonucleotide plant will provide a production capacity of 14 mole per year, which forecasts ST Pharm to become the world's largest leading CDMO in oligonucleotide production in 2025, in terms of capacity.